Mather Group LLC. Buys 76 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Mather Group LLC. increased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.7% during the 4th quarter, Holdings Channel.com reports. The firm owned 1,685 shares of the medical equipment provider’s stock after acquiring an additional 76 shares during the quarter. Mather Group LLC.’s holdings in Intuitive Surgical were worth $568,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of Intuitive Surgical by 0.7% during the third quarter. Vanguard Group Inc. now owns 29,868,227 shares of the medical equipment provider’s stock valued at $8,730,184,000 after purchasing an additional 196,316 shares during the last quarter. Jennison Associates LLC lifted its holdings in Intuitive Surgical by 6.4% in the third quarter. Jennison Associates LLC now owns 4,585,190 shares of the medical equipment provider’s stock valued at $1,340,205,000 after buying an additional 274,692 shares during the period. Invesco Ltd. lifted its holdings in Intuitive Surgical by 6.6% in the third quarter. Invesco Ltd. now owns 3,750,490 shares of the medical equipment provider’s stock valued at $1,096,231,000 after buying an additional 232,205 shares during the period. Northern Trust Corp lifted its holdings in Intuitive Surgical by 3.4% in the third quarter. Northern Trust Corp now owns 3,514,421 shares of the medical equipment provider’s stock valued at $1,027,230,000 after buying an additional 115,059 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Intuitive Surgical by 0.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,030,415 shares of the medical equipment provider’s stock valued at $593,470,000 after buying an additional 17,477 shares during the period. 83.64% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, President David J. Rosa sold 80,710 shares of Intuitive Surgical stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $389.28, for a total transaction of $31,418,788.80. Following the completion of the sale, the president now owns 163,399 shares of the company’s stock, valued at approximately $63,607,962.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Intuitive Surgical news, EVP Myriam Curet sold 481 shares of Intuitive Surgical stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $386.09, for a total value of $185,709.29. Following the completion of the sale, the executive vice president now owns 298 shares in the company, valued at approximately $115,054.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President David J. Rosa sold 80,710 shares of Intuitive Surgical stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $389.28, for a total transaction of $31,418,788.80. Following the completion of the sale, the president now owns 163,399 shares of the company’s stock, valued at approximately $63,607,962.72. The disclosure for this sale can be found here. In the last 90 days, insiders sold 226,928 shares of company stock valued at $87,833,828. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Price Performance

Shares of ISRG opened at $371.70 on Thursday. The firm has a 50-day moving average of $385.79 and a 200-day moving average of $348.35. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $403.76. The company has a market cap of $131.85 billion, a PE ratio of 67.09, a price-to-earnings-growth ratio of 4.79 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The company had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company’s quarterly revenue was up 11.5% on a year-over-year basis. During the same quarter last year, the firm posted $1.00 EPS. Analysts expect that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ISRG. Citigroup increased their price objective on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Mizuho increased their price objective on shares of Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a report on Thursday, January 25th. Piper Sandler increased their target price on shares of Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a report on Friday, April 19th. Truist Financial increased their target price on shares of Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 24th. Finally, StockNews.com lowered shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $396.17.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.